Abstract: A method of passing an object on the side of the road by receiving a first signal from a first sensor configured to detect a presence of the object positioned on a shoulder of a road; determining a first value; assigning a first confidence value to a confidence level, wherein the first confidence value is associated with the first value; responsive to the first confidence value exceeding a confidence threshold, adjusting a first operating parameter of a vehicle; responsive to entering a threshold range of the object, receiving a second signal from a second sensor; determining a second value associated with the second signal; assigning a second confidence value to the confidence level, wherein the second confidence value is associated with the second value; responsive to the second confidence value exceeding a second confidence threshold, adjusting a second operating parameter of the vehicle.

Abstract: A refuse vehicle includes a chassis, an energy storage device, a body, a first electric power take-off system, and a second electric power take-off system. The energy storage device is supported by the chassis and is configured to provide electrical power to a prime mover. Activation of the prime mover selectively drives the refuse vehicle. The body is supported by the chassis. The first electric power take-off system is coupled to at least one of the body and the chassis, and includes a first motor that is configured to drive a first hydraulic pump to convert electrical power received from the energy storage device into hydraulic power. The second electric power take-off system is coupled to at least one of the body and the chassis, and includes a second motor that is configured to drive a second hydraulic pump to convert electrical power received from the energy storage device into hydraulic power.

Abstract: A vehicle includes an automated apparatus extending from the vehicle and a projection system. The projection system includes a projector positioned on the vehicle. The projector is configured to operate to provide a projection onto a ground surface, the projection covering a zone. The automated apparatus is configured to operate within the zone.

Abstract: Among other things, there is disclosed structure and methods for maintaining access to a location in the body while reducing or eliminating the potential for pulling an access device (e.g. a catheter) back through an opening. An introducer sheath includes a distal indented portion and a balloon, so that once placed in a desired location through tissue, the balloon can be inflated to anchor the sheath against retraction. In particular embodiments, structure and methods for accessing the pericardial cavity via the right atrial appendage are shown.

Abstract: A refuse vehicle includes multiple systems, each system including a sensor. The refuse vehicle also includes an automated check system. The automated check system includes processing circuitry configured to obtain sensor data from the sensor of each of the multiple systems, determine which of the multiple systems require manual inspection based on the sensor data, and operate a display screen to prompt a technician to manually inspect one or more of the multiple systems.

Abstract: A refuse vehicle includes a chassis, a body, a lock, a tailgate, an ejector, an actuator, a second actuator, and a processor. The body defines a receptacle for storing refuse. The lock is coupled to the body and is configured to releasably secure a movable tailgate. The receptacle contains the ejector. The ejector can transition from a first position that is spaced from the tailgate to a second position proximate the tailgate. The actuator is configured to transition the ejector from the first position to the second position. The second actuator is configured to move the tailgate. The processor is configured to selectively unlock the tailgate and transition the ejector from the first position to the second position in response to receiving a single input to thereby eject refuse from the receptacle without receiving multiple inputs.

Abstract: The present invention relates to the synthesis of 3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo [4,3-c] pyridine-5-carbonyl] indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a salt thereof, and related synthetic intermediate compounds.

Abstract: Systems and methods are provided to provide guidance to a user regarding management of a physiologic condition such as diabetes. The determination may be based upon a patient glucose concentration level. The glucose concentration level may be provided to a stored model to determine a state. The guidance may be determined based at least in part on the determined state.

Abstract: Nozzles, nozzle assemblies, and blaster assemblies featuring interchangeable nozzles having externally powered electrical components or accessories. A nozzle assembly may include a body. The body may have a projectile opening defined therethrough. The nozzle assembly may further include an electrical component that is attachable to the body. The nozzle assembly may further include an electrical connection member coupled to the body and the electrical component. The electrical connection member may be configured to electrically connect the electrical component to the blaster.

Abstract: A delivery system for an occlusive implant includes a delivery sheath assembly and a hub assembly. The delivery sheath assembly includes a delivery sheath defining a delivery lumen adapted to accommodate an occlusive implant releasably secured to a core wire. A proximal fitting is secured to the delivery sheath. The hub assembly includes a hub body, a distal hub secured relative to the hub body and adapted to engage the proximal fitting of the delivery sheath assembly, a proximal hub secured to the hub body, and a side port coupled to hub body and adapted for flushing an interior of the delivery system. The delivery system includes one or more features that are adapted to limit relative rotation between the delivery sheath assembly and the hub assembly when the core wire is rotationally locked to the proximal hub.

Abstract: Delivery devices for an occlusive implant and method for making and using delivery devices are disclosed. An example delivery device may include a delivery sheath having a sheath body and a distal tip region. A tip reinforcing member may be coupled to the distal tip region. The tip reinforcing member may define a plurality of distal arm segments. The distal arm segments are configured to shift between a first configuration and an expanded configuration. A core member may be slidably disposed within the delivery sheath. An occlusive implant may be releasably coupled to the core member.

Abstract: The invention relates to a particular enantiomer of a substituted heterocycle fused gamma-carboline, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, and pathways involving the dopamine D1 and D2 receptor signaling system.

Abstract: The invention relates to a particular substituted heterocycle fused gamma-carboline, in free, or pharmaceutically acceptable salt, and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), and/or pathways involving the dopamine D1 and D2 receptor signaling system.

Abstract: A multi-layer coating system includes: a first coating layer formed from a first coating composition including: a film forming resin; and a fluorescent and/or phosphorescent pigment that: (1) emits radiation at an emission wavelength in the range of from 400-1200 nanometers when excited by ultraviolet and/or visible radiation corresponding to an excitation wavelength of the fluorescent and/or phosphorescent pigment; and/or (2) emits radiation at an emission wavelength in the range of from 600-2500 nanometers when excited by visible and/or near infrared radiation corresponding to an excitation wavelength of the fluorescent and/or phosphorescent pigment; and a second coating layer disposed over at least a portion of the first coating layer, which is formed from a second coating composition including: a film forming resin; and a pigment that blocks radiation corresponding to the excitation and/or emission wavelength of the fluorescent and/or phosphorescent pigment in the first coating layer.

Abstract: The disclosure provides new transdermal pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising—(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

Abstract: The present disclosure includes a split ring wire bundle seal sleeve and an assembly technology for pressurized electrical feedthroughs. A kit of parts is also described.

Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.

Abstract: The disclosure provides new transdermal pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

Abstract: The disclosure provides methods for the treatment of Bipolar II Disorder, comprising administering to a patient in need thereof, a therapeutically effective amount of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form.

Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.